Driven by Innovation & Growth

Our mission is to promote innovation and growth through strengthened networks; advocacy; capital investment; talent attraction, development and retention; and advancing the next generation of leaders.

About Us

Virginia's Life Science Community By the Numbers

  • 3,433 Companies

    Life science companies in Virginia.

  • $8B Industry

    Life Science contributes $8B to Virginia's economy.

  • 30, 504 People

    Employed by Life Science companies in Virginia.

  • $107,281 Average Wage

    Average earnings of life science workers in Virginia.

  • 1,197 Clinical trials

    Biopharmaceutical industry-sponsored trials in Virginia per year.

News

07/20/2026

Virginia’s Advanced Pharmaceutical Manufacturing Tech Hub Secures Federal Investment to Launch End-to-End Commercialization Project

Alliance for Building Better Medicine, the coalition leading Virginia’s Advanced Pharmaceutical Manufacturing (APM) Tech Hub, today announced a $15.97 million investment from the U.S. Economic Development Administration (EDA) to launch the End-to-End (E2E) Commercialization Project. The initiative will help establish a domestic commercialization pathway connecting innovation, manufacturing, and patients. Led by Civica, Inc. (Civica Rx)

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE